CELGENE $117.70

down -1.66


17/6/2013 04:17 PM  |  NASDAQ : CELG  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
Last Trade: 117.70
Trade Time: Jun 17 4:04 PM Eastern Daylight Time
Change: -1.66 (-1.39 %)
Prev Close: 119.36
Open: 120.43
Bid: 117.65
Ask: 118.15
Quotes displayed are delayed by 15 minutes. Market data is provided by Telvent DTN
Get Trend Analysis Icon Get CELG Trend Analysis - it has outperformed the S&P 500 by 55%

ETF Alternatives



People viewing CELG also viewed: , , , ,

Competitors

Ticker Name Volume % Change
CHHL CHINA HOLDINGS 1.0K +1.50%
GTHR GENETHERA 11.1K +1.29%
CKGT CHINA KANGTAI CACTUS BIO 71.5K +0.79%
COBI COMPASS BIOTECHNOLOGIES 10.0K +0.50%
ARYX ARYX THERAPEUTICS 325.0K +0.45%

Insider Transactions

Date Name Title Volume Trade Price Holding Change
6/16/2013 HUGIN ROBERT J see remarks -3,370 $119.36 -0.66%
6/5/2013 MARIO ERNEST Director 15,000 $59.89 23.07%
5/30/2013 HUGIN ROBERT J see remarks -68,087 $123.58 -11.84%
5/29/2013 MARIO ERNEST Director 600 $123.72 0.94%
5/29/2013 MARIO ERNEST Director 400 $123.73 0.62%
Data provided by Insiderslab.com. To read detailed Insider Trading Research Report for (CELG), click here.
View All

CELG Stock Analysis

  1. Data on BMY/ AbbVie's elotuzumab - Analyst Blog

    (SNTS,BMY,CELG,ABBV )
    Bristol-Myers and partner AbbVie presented data on elotuzumab from a phase II study.
  2.

    Good News for Celgene's Revlimid - Analyst Blog

    (CELG,BIIB,JAZZ,ANIK )
    The EC approved Revlimid for MDS.
  3.

    Apremilast Data Presented by Celgene - Analyst Blog

    (PFE,CELG,AMGN,BIIB )
    Celgene presented data from the PALACE 3 study on apremilast.
  4.

    Warning: This Might Be The Most Overvalued Sector In The Market

    (AMGN,GILD,CELG )
    When it comes to assessing the outlook for drugmakers, investors really only care about the pipeline of new drugs. After all, existing drugs eventually lose patent protection, and when that happens, a large hole in the income statement can appear. Just a few days ago, I looked at the prospects for traditional drugmakers and concluded that Bristol-Myers Squibb (NYSE: BMY) and Eli Lilly (NYSE: LLY) are among the handful of Big Pharma firms with appealing pipelines. The renewed pipelines are in some instances giving those stocks a solid boost, with shares rising at an impressive pace over the past year.
  5.

    Amgen Chased By The Bubble

    (AMGN,PFE,SNY,TEVA,CELG,NVO,MRK,HSP,ABT,AFFY,BIIB,GILD )
    Amgen really needs the pipeline to come through to support this valuation.
Free Reports
  1.

    21-page Book on Learning to Trade Options on Futures!

    Not too complex. Not too basic. Just enough information to help you ask the right questions so you can start using these markets.
  2.

    View the Portfolios of the Worlds Top Investors, FREE!

    Learn from Warren Buffett, George Soros and More!
  3.

    4 Best Buy ETFs for the Current Market

    Don't miss this FREE Special Report from Forbes' fund and ETF expert Jim Lowell.
Marketplace
Trading Center